Cytoplasmic membrane cholesterol and doxorubicin cytotoxicity in drug-sensitive and multidrug-resistant human ovarian cancer cells - PubMed (original) (raw)
Affiliations
- PMID: 8364256
Cytoplasmic membrane cholesterol and doxorubicin cytotoxicity in drug-sensitive and multidrug-resistant human ovarian cancer cells
A Mazzoni et al. Oncol Res. 1993.
Abstract
The possible involvement of cholesterol (CHOL) in the cellular transformations leading to the acquisition of the multidrug-resistance (MDR) phenotype has been evaluated in human ovarian cancer cells. To this end, the A2780 cell line and the 52-fold doxorubicin (DX)-resistant counterpart A2780-DX3 were analyzed under two different growth conditions: standard culture medium (FCS medium), or medium deprived of CHOL (LPDS medium). The following variables were investigated: free and esterified cytoplasmic membrane CHOL, cell growth, DX uptake and cytotoxicity, and low-density lipoprotein uptake and degradation (as indirect variables of CHOL homeostasis). The impact of the calcium antagonist verapamil (VER) on these variables was assessed. The results obtained indicate that under standard growth conditions, A2780 and A2780-DX3 cells are different not only with respect to DX uptake and sensitivity, but also with respect to membrane CHOL content and the ratio of free-to-esterified CHOL. The deprivation of lipoproteins in the culture medium, apart from slowing cell growth, induced a decrease in the cytoplasmic membrane CHOL content (mainly of the esterified form) that was particularly evident in A2780 sensitive cells. In LPDS medium, a reduced DX uptake occurred in both cell lines, but to a greater extent in A2780 cells, in which DX cytotoxicity decreased to values comparable to that of A2780-DX3 resistant cells. Restoration of DX sensitivity was achieved with the addition of 10 microM VER.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
- Membrane gangliosides and immuno-mediated cytolysis in drug sensitive and treatment-induced multidrug resistant human ovarian cancer cells.
Mazzoni A, Trave F, Fabbri M, Leto G, Ghidoni R. Mazzoni A, et al. Anticancer Res. 1991 Nov-Dec;11(6):2181-5. Anticancer Res. 1991. PMID: 1776860 - Reversal of "atypical"-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3.
Cimoli G, Valenti M, Parodi S, Mazzoni A, De Sessa F, Conte P, Russo P. Cimoli G, et al. Oncol Res. 1993;5(8):311-23. Oncol Res. 1993. PMID: 8012063 - The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ. Horowitz NS, et al. Gynecol Oncol. 2004 Jul;94(1):67-73. doi: 10.1016/j.ygyno.2004.03.047. Gynecol Oncol. 2004. PMID: 15262121
Cited by
- Development and Characterization of Solid Lipid Nanoparticles Loaded with a Highly Active Doxorubicin Derivative.
Stella B, Peira E, Dianzani C, Gallarate M, Battaglia L, Gigliotti CL, Boggio E, Dianzani U, Dosio F. Stella B, et al. Nanomaterials (Basel). 2018 Feb 16;8(2):110. doi: 10.3390/nano8020110. Nanomaterials (Basel). 2018. PMID: 29462932 Free PMC article. - Membrane-active host defense peptides--challenges and perspectives for the development of novel anticancer drugs.
Riedl S, Zweytick D, Lohner K. Riedl S, et al. Chem Phys Lipids. 2011 Nov;164(8):766-81. doi: 10.1016/j.chemphyslip.2011.09.004. Epub 2011 Sep 16. Chem Phys Lipids. 2011. PMID: 21945565 Free PMC article. Review. - Rafts as missing link between multidrug resistance and sphingolipid metabolism.
Hinrichs JW, Klappe K, Kok JW. Hinrichs JW, et al. J Membr Biol. 2005 Jan;203(2):57-64. doi: 10.1007/s00232-004-0733-4. J Membr Biol. 2005. PMID: 15981711 Review. No abstract available. - Drug resistance in breast cancer cells: biophysical characterization of and doxorubicin interactions with membrane lipids.
Peetla C, Bhave R, Vijayaraghavalu S, Stine A, Kooijman E, Labhasetwar V. Peetla C, et al. Mol Pharm. 2010 Dec 6;7(6):2334-48. doi: 10.1021/mp100308n. Epub 2010 Nov 11. Mol Pharm. 2010. PMID: 20958074 Free PMC article. - Lipid rafts: dream or reality for cholesterol transporters?
Orlowski S, Coméra C, Tercé F, Collet X. Orlowski S, et al. Eur Biophys J. 2007 Nov;36(8):869-85. doi: 10.1007/s00249-007-0193-8. Epub 2007 Jun 19. Eur Biophys J. 2007. PMID: 17576551 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical